Comprehensive Lung Health (CLUES)

November 6, 2026 updated by: Ankit Bharat, Northwestern University

Comprehensive Lung Health Screening and Its Utility for Early Risk and Disease Stratification

Respiratory illnesses are a leading cause of morbidity and mortality worldwide, yet their prevalence in the general population remains poorly characterized. Computed tomography (CT) is the most effective diagnostic tool for identifying respiratory illnesses that cause changes to the lung parenchyma, such as pulmonary infections, fibrosis, and nodules. The diagnostic power of CT led the US Preventive Services Task Force (USPSTF) to issue lung cancer screening guidelines. In this prospective, observational cohort study, the study team will recruit 10,000 individuals aged 21 to 85 years, stratified into three cohorts: Cohort 1 (Medical Indication Group), Cohort 2 (Guideline-Based Screening Group), and Cohort 3 (Asymptomatic Research Low-Dose CT [LDCT] Group). The primary analysis will estimate the baseline cross-sectional prevalence of LDCT-detectable pulmonary findings in Cohort 3. Secondary analyses will compare baseline LDCT findings across all three cohorts and evaluate baseline associations between risk/exposure variables and CT findings. Exploratory follow-up analyses will use clinical data from the electronic health record (EHR), as available, for up to 5 years after the baseline/index CT. This study has the potential to transform health screening strategies, reduce disease burden, and improve health outcomes across diverse populations.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

10000

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Illinois
      • Chicago, Illinois, United States, 60611
        • Recruiting
        • Northwestern Medicine
        • Principal Investigator:
          • Ankit Bharat, MD
        • Contact:
        • Sub-Investigator:
          • Momen Wahidi, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

All Cohorts:

•Adults 21 through 85 years of age.

Cohort 1:

•Clinical indication for chest CT, such as suspected lung pathology, abnormal chest imaging, or pulmonary symptoms requiring further evaluation. Cohort 1 activities are routine clinical care; research activity is secondary data use.

Cohort 2:

•Individuals who currently meet USPSTF criteria for LDCT lung cancer screening. Cohort 2 activities are routine clinical care; research activity is secondary data use.

Cohort 3:

  • Asymptomatic individuals who:
  • Do not have a clinical indication for chest CT
  • Do not meet current USPSTF criteria for LDCT lung cancer screening
  • Able to provide informed consent

Exclusion Criteria:

All Cohorts:

•Individuals below the age of 21 and above the age of 85.

Cohort 3:

  • Meets USPSTF guideline-based indications for LDCT lung cancer screening or has a clinical indication for chest CT.
  • Any chest CT within the prior 2 years
  • Pregnancy
  • In active surveillance or treatment for a current cancer diagnosis, or a recent cancer diagnosis requiring intervention within 5 years of the baseline assessment.
  • Unable to provide informed consent or lacks decision-making capacity
  • McGaw medical students, residents, and fellows, consistent with NU/FSM policy, to reduce coercion or undue influence. Employees may participate only under the safeguards described in the vulnerable populations section.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Screening
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Cohort 1 (Medical Indication Group)

Adults 21 through 85 years of age with a clinical reason for chest CT, such as suspected lung pathology, abnormal chest imaging, or pulmonary symptoms requiring further evaluation. Cohort 1 participants undergo CT and follow-up as part of routine clinical care. Study activity is limited to secondary use of routine-care data under waiver of consent and HIPAA authorization.

No Intervention: Cohort 2 (Guideline-Based Screening Group)

Adults 21 through 85 years of age who meet current USPSTF criteria for LDCT lung cancer screening. Cohort 2 participants undergo screening and follow-up as part of routine clinical care. Study activity is limited to secondary use of routine-care data under waiver of consent and HIPAA authorization.

Active Comparator: Cohort 3 (Asymptomatic Research LDCT Group)

Adults 21 through 85 years of age who are asymptomatic, do not have a clinical indication for chest CT, and do not meet current USPSTF lung cancer screening criteria. Cohort 3 participants will provide informed consent and HIPAA authorization before undergoing a single LDCT of the chest billed to the study.

A low-dose CT scan is an X-ray procedure where a high-speed computer is used to make multiple images of your chest area using the least amount of radiation possible without reducing the diagnostic quality of the exam.

Other Names:
  • LDCT

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Primary Endpoint
Time Frame: For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.

Baseline prevalence of CT-detectable pulmonary abnormalities in Cohort 3.

For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Secondary Endpoint 1
Time Frame: For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.

Comparative baseline prevalence of pulmonary findings across Cohorts 1, 2, and 3.

For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
Secondary Endpoint 2
Time Frame: For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.

Prevalence and reported severity of coronary artery calcification in Cohort 3 and across cohorts, using the final radiology report categories, such as absent/present or none/mild/moderate/severe when available.

For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
Secondary Endpoint 3
Time Frame: For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.

Prevalence of bone-density-related abnormalities or vertebral compression fracture findings across all three cohorts using the final radiology report terminology.

For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
Secondary Endpoint 4
Time Frame: For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.

Associations between baseline defined variables and LDCT-detectable findings.

For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
Secondary Endpoint 5
Time Frame: 5 years

EHR-derived outcomes for up to 5 years after baseline/index LDCT, including clinically documented diagnoses, additional imaging, procedures, treatments, and mortality as available.

5 years

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Exploratory Endpoint 1
Time Frame: 6 years

Subgroup analyses by age, sex, race/ethnicity, smoking status, and exposure categories.

6 years
Exploratory Endpoint 2
Time Frame: 6 years

Exploratory prediction models if event counts support model development.

6 years
Exploratory Endpoint 3
Time Frame: 6 years

Descriptive analyses of downstream clinical evaluation after baseline CT findings.

6 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Ankit J Bharat, MD, Northwestern Medicine Canning Thoracic Institute
  • Principal Investigator: Momen J Wahidi, MD, Northwestern Medicine Canning Thoracic Institute

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 16, 2025

Primary Completion (Estimated)

September 16, 2030

Study Completion (Estimated)

December 30, 2031

Study Registration Dates

First Submitted

November 6, 2026

First Submitted That Met QC Criteria

November 6, 2026

First Posted (Actual)

November 12, 2026

Study Record Updates

Last Update Posted (Actual)

November 12, 2026

Last Update Submitted That Met QC Criteria

November 6, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Upon PI approval, de-identified, coded data may be shared with other investigators conducting IRB-approved projects to establish a longitudinal data repository to support future IRB-approved research on early detection, prevention, and management of pulmonary and cardiothoracic conditions. Genetic testing, biospecimen collection, quantitative imaging re-analysis, or other analyses are not currently planned. Recipients will be required to adhere to institutional data protection standards.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe